Otros idiomas Jiangsu Recbio Technology Co., Ltd.

Acciones

2179

CNE1000057K9

Precio de cierre Hong Kong S.E. Otros sitios de cotización 00:00:00 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
9,13 ^CNY	0,00 %		-1,72 %	-15,93 %

27/03	Jiangsu Recbio Technology Co., Ltd. y Shanghai Rongsheng Biotech Co.,Ltd. Firman un Acuerdo de Cooperación Estratégica sobre el Proyecto de la Nueva Vacuna Adyuvante	CI
21/03	La pérdida de Jiangsu Recbio Technology se reduce en 2023	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Jiangsu Recbio Technology Co., Ltd. and Shanghai Rongsheng Biotech Co.,Ltd. Sign Strategic Cooperation Agreement on the New Adjuvant Vaccine Project	27/03
Jiangsu Recbio Technology's Loss Narrows in 2023	21/03
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines	29/12
Jiangsu Recbio Technology Co., Ltd. Announces Positive Results in the Interim Analysis of the Clinical Trial of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 in the Philippines	29/12
Jiangsu Recbio Logs Positive Results from Philippines Trial Of Shingles Vaccine	29/12
Jiangsu Recbio Technology to Extend Validity Period of Share Sale	28/12
Jiangsu Recbio Technology Co., Ltd.(SEHK:2179) added to S&P Global BMI Index	18/09/23
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23
China Approves Recbio's Clinical Trial Application for Shingles Vaccine	27/07/23
Jiangsu Recbio Technology Co., Ltd. Announces Acceptance of Clinical Trial Application for the Novel Adjuvanted Recombinant Shingles Vaccine REC610 in China and Overseas Clinical Trial Progress	26/07/23
Jiangsu Recbio Technology Co., Ltd. - Inclusion of Recbio in the MSCI China Small Cap Index	18/05/23
Jiangsu Recbio Technology Selected for Morgan Stanley Capital International China Small Cap Index	17/05/23
Jiangsu Recbio Technology Co., Ltd. Announces Directorate Appointments	11/05/23
Chinese Securities Regulator Approves Jiangsu Recbio Technology's Share Issuance; Stock Sinks 3%	20/04/23
Pfizer signs strategic cooperation pact with China's Sinopharm	13/04/23
Jiangsu Recbio Technology Co., Ltd. Announces Resignation of Feng Tao as Non-Executive Director and A Member of the Nomination Committee	03/04/23
Certain H Shares of Jiangsu Recbio Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 30-MAR-2023.	30/03/23
Mongolia Grants Emergency Approval for Jiangsu Recbio's Recombinant COVID-19 Vaccine	21/03/23
Jiangsu Recbio Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Jiangsu Recbio Technology Co., Ltd.

Acciones

2179

CNE1000057K9

Otros idiomas

Filtros